Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.55 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25834265 | 0.86 | P2RX7 (0.45) | CXCR3CYP2A13SIGMAR1P2RX7ALDH1A1 | |
| SCHEMBL11799876 | 0.79 | ALDH1A1 (0.62) | CYP2A13SIGMAR1P2RX7ALDH1A1LMNA | |
| SCHEMBL30798198 | 0.76 | KMT2A (0.57) | CYP2A13SIGMAR1P2RX7ALDH1A1LMNA | |
| SCHEMBL10493799 | 0.74 | P2RX7 (0.47) | CYP2A13GAASIGMAR1P2RX7ALDH1A1 | |
| SCHEMBL29606737 | 0.74 | CRBN (0.64) | DDB1CRBNGAAALDH1A1LMNA | |
| SCHEMBL23121000 | 0.74 | CRBN (0.64) | DDB1CRBNGAAALDH1A1LMNA | |
| SCHEMBL11290437 | 0.73 | DBH (0.43) | CXCR3CYP2A13SIGMAR1P2RX7ALDH1A1 | |
| SCHEMBL26017324 | 0.72 | P2RX7 (0.50) | CYP2A13SIGMAR1P2RX7ALDH1A1LMNA | |
| SCHEMBL6827489 | 0.71 | DDB1 (1.00) | DDB1CRBNGAASIGMAR1KDM4E | |
| SCHEMBL24508364 | 0.71 | KDM4E (0.73) | CYP2A13SIGMAR1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-06-17 | — | — | US | disclosed |
| WO-2017161119-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | CD4, GZMB, CRBN | DDB1 2798/4885CRBN 3/4885CXCR3 59/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | DDB1 3336/4885CRBN 2/4885CXCR3 79/4885 |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, GZMB, CRBN | DDB1 2798/4885CRBN 3/4885CXCR3 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.